Pareto publishes research report setting price target of SEK 25 per share as new analyst assumes coverage
Hørsholm, Denmark, September 22, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities has published a new research report on ExpreS2ion in September in which a new analyst, Marietta Miemietz, assumes coverage of the Company.
“The pipeline is progressing at a rapid pace. Bavarian Nordic commenced recruitment into the phase III trial for the COVID-19 vaccine ABNCoV2 earlier this month and aims for launches in the EU & US in 2023. In mid-2023, the company expects to finish pre-clinical work on the HER2-targeted breast cancer vaccine, potentially paving the way to first-in-human testing in 2024. We reiterate our Buy recommendation and set a price target of SEK 25/share.” – Pareto Securities
The report provides an assessment of ExpreS2ion’s pipeline, including potential near-term news flow, sum-of-the-parts analysis for estimating fair value per share and prospective financial estimates. Pareto sets a price target of SEK 25 per share based on the sum-of-the-parts valuation analysis, with upside to SEK 48 per share should COVID-19 become endemic in key Western markets.
The research report is available on the Analyst Reports page of ExpreS2ion’s investor website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.